Discovery and validation of urinary biomarkers for detection of renal cell carcinoma

Maria Frantzi, Jochen Metzger, Rosamonde E Banks, Holger Husi, Julie Klein, Mohammed Dakna, William Mullen, Jonathan J Cartledge, Joost P Schanstra, Korbinian Brand, Markus A Kuczyk, Harald Mischak, Antonia Vlahou, Dan Theodorescu, Axel S Merseburger

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)


Clear cell renal cell carcinoma (RCC) has the highest incidence among the renal malignancies, often presenting non-specific or no symptoms at all. Moreover, with no diagnostic marker being available so far, almost 30% of the patients are diagnosed with metastatic disease and 30-40% of the patients initially diagnosed with localized tumor relapse. These facts introduce the clinical need of early diagnosis. This study is focused on the investigation of a marker model based on urinary peptides, as a tool for the detection of RCC in selected patients at risk. Upon evaluation of the marker model in an independent blinded set of 76 samples, 80% sensitivity and 87% specificity were reported. An additional dataset of 1077 samples was subsequently employed for further evaluation of the specificity of the classifier.
Original languageEnglish
Pages (from-to)44-58
Number of pages15
JournalJournal of Proteomics
Publication statusPublished - 1 Feb 2014


Dive into the research topics of 'Discovery and validation of urinary biomarkers for detection of renal cell carcinoma'. Together they form a unique fingerprint.

Cite this